Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept 2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operations before changes in working capital
49 080 EUR
18 714 EUR
Adjustments for increase (decrease) in other liabilities
1 787 EUR
321,000 EUR
Adjustments for decrease (increase) in other current assets
4 147 EUR
353,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
53,000 EUR
14,000 EUR
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, intangible assets other than goodwill, investment property and other non-current assets
77,000 EUR
16,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.